Back to top
more

Xencor (XNCR)

(Delayed Data from NSDQ)

$19.98 USD

19.98
375,500

+0.75 (3.90%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $19.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XNCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Xencor, Inc. [XNCR]

Reports for Purchase

Showing records 181 - 200 ( 216 total )

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 181

08/12/2015

Daily Note

Pages: 30

2015 HCMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 182

08/04/2015

Company Report

Pages: 6

2Q15 Earnings; Rich Pipeline Continues to Advance, Reiterate OP and Raising PT to $27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 183

06/28/2015

Daily Note

Pages: 6

R-D Day Highlights Pipeline, with Upcoming Catalysts, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 184

06/28/2015

Daily Note

Pages: 6

R-D Day Highlights Pipeline, with Upcoming Catalysts, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 185

06/10/2015

Daily Note

Pages: 5

Reports Full Data from Ph1/2a Study of ''5871 in Rheumatoid Arthritis; Supports Potential in IgG4-RD

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 186

05/04/2015

Company Report

Pages: 7

1Q15 Results, Recent Financing Provides Nearly Five-Year Cash Runway, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 187

02/19/2015

Company Report

Pages: 7

4Q14 Earnings, Pipeline Progressing with Cash Runway through 2016, Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 188

02/16/2015

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 189

01/29/2015

Company Report

Pages: 5

''5871 and ''7195 Demonstrate Clinical Activity, Additional Validating Data Expected this Year, Reiterate OP and Raising PT to $22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 190

01/23/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 26

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 191

01/16/2015

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 192

01/11/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 12

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 193

01/05/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 5

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 194

12/29/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 195

12/19/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 196

12/18/2014

Daily Note

Pages: 4

Announces Bispecific Collaboration Agreement with Novo Nordisk for Undisclosed Target

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 197

12/14/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 198

12/08/2014

Daily Note

Pages: 6

Presents Preclinical Update on Bispecific Programs and XmAb13677/MOR208 Clinical Data at ASH

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 199

12/08/2014

Daily Note

Pages: 6

Presents Preclinical Update on Bispecific Programs and XmAb13677/MOR208 Clinical Data at ASH

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 200

11/10/2014

Company Report

Pages: 6

Q3 EPS; Bispecific Antibody Chosen; ''7195 Early Results on Tap for January ''15

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party